Hypoparathyroidism Market to Eyewitness Robust Expansion Growing at a 17.7% CAGR During the Study Period [2018-2030], Predicts DelveInsight

- The rising prevalence of Head and Neck cancer and related surgeries will drive the patient pool, whereas emerging treatments such as TransCon PTH and Encaleret should drive the future Hypoparathyroidism therapeutic landscape in the 7MM

LAS VEGAS, June 23, 2021 /PRNewswire/ -- DelveInsight's "Hypoparathyroidism Market" report provides a thorough comprehension of the Hypoparathyroidism historical and forecasted epidemiology and the Hypoparathyroidism market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Hypoparathyroidism market report also proffers an analysis of the current Hypoparathyroidism treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

 Some of the necessary takeaways from the Hypoparathyroidism Market Research Report 

• Several key pharmaceutical companies such as Takeda, Ascendis Pharma, EnteraBio, Bridgebio, Calcilytix Therapeutics, and others are developing novel products to improve the Hypoparathyroidism treatment outlook. 
• Natpara (parathyroid hormone/rhPTH [1-84]) is the only approved drug for the Hypoparathyroidism treatment approved in the US and Europe.
• Ascendis Pharma's TransCon PTH showed strong data in a Phase II trial. As a result, of all the therapies, the majority of the Hypoparathyroidism market share should be accommodated by TransCon PTH, which is expected to generate a market size of USD 1,615 million in 2030. 
• TransCon platform could prove to be a major value driver for the Hypoparathyroidism market, as it is a long-acting version of Parathyroid hormone (PTH) that eliminated the need for a standard of care and maintained calcium in the normal range, making TransCon PTH a competitor of Natpara. Apart from TransCon PTH, EB612 has also continued to make good progress for Hypoparathyroidism. 
• With increasing Hypoparathyroidism prevalence, the research picks up for the drug; it is likely to provide an appropriate environment for newer products to be profitable. The US FDA and EMA support the Hypoparathyroidism pipeline by encouraging the drug development process through different types of designations. Moreover, as awareness of the disease rises, more companies are shifting their focus on the upcoming therapeutic Hypoparathyroidism pipeline. In the upcoming years, several new products, including calcium-sensing receptor antagonist, PTH (1–34), and others, might launch in the Hypoparathyroidism market, indicating that the market is becoming increasingly competitive. 
• Nevertheless, the unavailability of an approved therapy for the treatment of Hypoparathyroidism is a major factor restraining the growth of the global Hypoparathyroidism drug market.

For further information on Market Impact by Therapies, visit: Hypoparathyroidism Drugs Market Analysis 

Hypoparathyroidism is characterized by hypocalcemia and hyperphosphatemia due to a lack of parathyroid hormone (PTH) secretion or action. DelveInsight estimates that the total Hypoparathyroidism prevalent population in the 7MM was estimated to be around 262,542 cases in 2020. It has also been observed that Hypoparathyroidism affects females more than males.

The Hypoparathyroidism Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total Prevalent Cases of Hypoparathyroidism
• Diagnosed Prevalent Cases of Hypoparathyroidism
• Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism
• Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism
• Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism
• Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism

Get a complete epidemiological segmentation @ Hypoparathyroidism Epidemiological Analysis 

Hypoparathyroidism Treatment Market 

Traditional treatment of Chronic Hypoparathyroidism includes supplemental calcium along with active vitamin D metabolites. There are several different classes of drugs, human PTH, calcium-sensing receptor antagonist, hormone replacement therapy available in the market for Hypoparathyroidism treatment.

Hypoparathyroidism that does not respond adequately to calcium and vitamin D supplementation may need treatment with recombinant human parathyroid hormone (rhPTH). In January 2015, the USFDA approved the use of recombinant human parathyroid hormone (1–84) (rhPTH[1–84]), Natpara, as a treatment for adult patients with Chronic Hypoparathyroidism who are uncontrolled with conventional therapy (calcium and activated vitamin D). Parathyroid hormone (PTH) raises serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption, and increasing bone turnover, releasing calcium into the circulation. 

The drug launched in the US market in April 2015 was the only therapy approved for Hypoparathyroidism patients till September 2019 until Takeda issued a US recall of Natpara after small rubber particles were found in some samples of the solution as a result of the reusable injection system. 

Ascendis Pharma's TransCon PTH is a long-acting version of PTH that eliminated the need for a standard of care – defined as active vitamin D and ≤600 mg/day of calcium supplements and maintained calcium in the normal range. 

TransCon platform can become a competitor to Natpara. Apart from TransCon PTH, EB612 (PTH 1-34) has also continued to make good progress for Hypoparathyroidism. It has been observed that oral PTH is effectively delivered into the bloodstream and activates PTH-dependent biological pathways inadequately activated in Hypoparathyroidism patients. 

The Hypoparathyroidism market dynamics are anticipated to change during the forecasted period owing to the rising cases of Hypoparathyroidism in various regions that lead to increased demand for advanced diagnostic drugs. Moreover, the market will also grow due to the expected launch of emerging therapies. There are many pipeline therapies such as TransCon PTH (Ascendis Pharma), EB612 (EnteraBio), Encaleret (Bridgebio/Calcilytix Therapeutics), and others that are under development for the prevention and treatment of Hypoparathyroidism. However, there might be setbacks to Hypoparathyroidism market growth because of the already available off-labeled drugs, which might offer tough competition to emerging ones. In addition, the market might be hindered due to the lengthy clinical approval cycles and most trials, which do not fulfill treatment guidelines established by regulatory authorities.

Scope of the Hypoparathyroidism Market Insight Report 

• Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
• Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
• Hypoparathyroidism Markets Segmentation: By Geographies and By Hypoparathyroidism Therapies (Historical and Forecasted, Current and Upcoming) 
• Dominant Market Companies investigating its candidates for Hypoparathyroidism: Shire (Takeda), Ascendis Pharma, EnteraBio, Bridgebio, Calcilytix Therapeutics, and several others. 
• Analysis: Comparative and conjoint analysis of emerging therapies. 
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Hypoparathyroidism Therapeutics Market

Table of Contents 

Browse full report with detailed TOC with charts, figures, tables @ Hypoparathyroidism Diagnostics Market Report

View Related Reports

• Hypoparathyroidism Epidemiology Forecast 

DelveInsight's Hypoparathyroidism - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hypoparathyroidism in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• Hypoparathyroidism Pipeline

Hypoparathyroidism Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across 7MM. The key players involved in Hypoparathyroidism drug development are Ascendis Pharma, Calcilytix Therapeutics, Amolyt Pharma, AEterna Zentaris Inc, Chugai Pharmaceutical, Entera Bio, Extend Biosciences, GC Pharma, Aerami Therapeutics, Sigilon Therapeutics, Alizé Pharma, and others.

• Secondary Hyperparathyroidism Market

DelveInsight's Secondary Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Hyperparathyroidism Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Hyperparathyroidism - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Hyperparathyroidism.

• Medullary Thyroid Cancer Market 

DelveInsight's Medullary Thyroid Cancer - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

Browse Blog Posts

• Migraine Market
• Pacemakers Pipeline Landscape

For ASCO updates, browse here:- 

• Cholangiocarcinoma Highlights: ASCO 2021
• Sarcoma Highlights: ASCO 2021
• Esophageal Squamous Cell Carcinoma Highlights: ASCO 2021
• Breast Cancer Highlights - ASCO 2021
• Pancreatic Cancer Highlights: ASCO 2021

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Contact Us:
Shruti Thakur
info@delveinsight.com  
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg